BioSpace News Archive

STAAR Surgical Company today announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2021 on Wednesday, February 23, 2022 after the market close.

Assembly Biosciences, Inc. announced that John McHutchison, AO, MD, chief executive officer and president, will participate in a virtual fireside chat during the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17, 2022 at 3:40 p.m. ET.

Athenex, Inc. announced that Johnson Lau, CEO and Board Chairman, and Daniel Lang, President, Athenex Cell Therapy, will present at the 11th Annual SVB Leerink Global healthcare Conference on Thursday, February 17, 2022, at 3:00 P.M. ET.

Vincerx Pharma, Inc. announced that Vincerx’s management team will participate in a fireside chat and one-on-one investor meetings at the SVB Leerink 11th Annual Global Healthcare Conference, to be held virtually February 14-18, 2022.

Codex DNA, Inc., a pioneer in automated benchtop synthetic biology systems, announced that members of its management team will be participating in the SVB Leerink 11th Annual Global Healthcare Conference.

Tempest Therapeutics, Inc. announced that management will present at the 11th Annual SVB Leerink Healthcare Conference on Wednesday, February 16, 2022 at 2:20 p.m. ET.

electroCore, Inc., a commercial-stage bioelectronic medicine company, announced top line data from three abstracts being presented at the American Heart Associations’ 2022 International Stroke Conference on the possible role of nVNS in the acute treatment of stroke.

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced updated interim clinical data from the ongoing Phase 1/2 clinical trial of 4D-310 in patients with Fabry disease at the 18th Annual WORLDSymposium.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the fourth quarter 2021 on Tuesday, February 22 at 4:30 p.m. ET / 1:30 p.m. PT.

Sunovion Pharmaceuticals Inc. (Sunovion) and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) today announced that the first patient has been randomized in SEP380-301, a Phase 3 clinical study evaluating non-racemic amisulpride (SEP-4199) for the treatment of major depressive episodes associated with bipolar I disorder (bipolar depression).